33 unknown, 19 completed, 19 recruiting, 12 terminated. 60 Phase 2, 14 Phase 1, 6 Not applicable, 3 Phase 3.
Follow NSCLC Stage IV: new trials by email Literature Review of NSCLC Stage IV trials Research Report on NSCLC Stage IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC Glecirasib, Ivonescimab - NSCLC Stage IV, KRAS G12C | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 42 | 2026-03-01 | 2026-01-14 |
| A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy sacituzumab tirumotecan - NSCLC Stage IV, EGFR Gene Mutation | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 25 | 2026-02-01 | 2026-04-23 |
| Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg Firmonertinib 160mg - NSCLC Stage IV, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 28 | 2026-01-01 | 2026-01-21 |
| Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy N-803, Tislelizumab, Docetaxel - NSCLC Stage IV | Phase 3 | Recruiting | ImmunityBio, Inc. | 507 | 2025-10-01 | 2026-11-02 |
| TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% NSCLC Stage IV, PD-L1 Gene Mutation | Recruiting | Antalya Training and Research Hospital | 150 | 2025-09-15 | 2026-04-30 | |
| Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab - NSCLC Stage IV, Brain Metastases, Adult | Phase 2 | Recruiting | Maastricht University Medical Center | 25 | 2025-04-24 | 2025-05-06 |
| Outpatient Pulmonary Rehabilitation in Non-small-cell Lung Cancer Receiving Immunotherapy outpatient pulmonary rehabilitation - NSCLC Stage IV | Not applicable | Recruiting | Karl Landsteiner Institute for Lung Research and Pneumological Oncology | 70 | 2025-01-27 | 2025-06-26 |
| Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC Cemiplimab, Placebo - NSCLC Stage IV | Phase 2 | Active not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 136 | 2025-01-14 | 2026-06-23 |
| HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC HY1272 - NSCLC Stage IV | Phase 1 | Not yet recruiting | Newsoara Biopharma Co., Ltd. | 40 | 2024-12-01 | 2024-01-23 |
| A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) Cabozantinib, Atezolizumab - Lung Cancer, NSCLC Stage IV | Phase 2 | Not yet recruiting | Jun Zhang, MD, PhD | 40 | 2024-12-01 | 2024-05-08 |
| Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC Repotrectinib - NSCLC Stage IV, NSCLC, Stage III | Phase 2 | Recruiting | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer | 30 | 2024-10-01 | 2026-07-07 |
| Cancer Patient Remote Monitoring for Timely Communication Study NSCLC Stage IV | Unknown | Asklepios proresearch | 100 | 2024-10-01 | 2024-10-02 | |
| Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer Stereotactic Body Radiotherapy, second-line systemic therapy - Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV | Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 104 | 2024-09-01 | 2024-08-30 |
| ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer Alectinib, Brigatinib, Lorlatinib 100 mg - NSCLC Stage IV, Sex Disorder | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 80 | 2024-08-05 | 2024-08-09 | |
| Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis PD-L1/PD-1 inhibitor and chemotherapy, SRT or WBRT - NSCLC Stage IV, Brain Metastases | Phase 2 | Recruiting | Fudan University | 54 | 2024-07-01 | 2024-08-28 |
| Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis PD-1/PD-L1 inhibitor plus chemotherapy, SRT/WBRT - NSCLC Stage IV | Phase 2 | Completed | Fudan University | 40 | 2024-07-01 | 2026-09-14 |
| Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC Peptide vaccine - NSCLC Stage IV, ALK Fusion Protein Expression | Phase 1 / Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 12 | 2024-05-13 | 2026-07-28 |
| Exercise in Patients With Advanced Non-small Cell Lung Cancer Exercise intervention - Advanced Lung Carcinoma, First Line Treatment | Not applicable | Unknown | University Hospital, Essen | 104 | 2024-05-01 | 2024-04-18 |
| Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy SBRT or LDRT, PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy - NSCLC Stage IV | Phase 2 | Unknown | Fudan University | 146 | 2024-04-10 | 2024-06-05 |
| AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer Immunotherapy, Chemotherapy - NSCLC Stage IV | Recruiting | IRCCS San Raffaele | 2000 | 2024-02-12 | 2025-01-23 |
Showing 20 of 101. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (101) · Lung Neoplasms (14) · Recurrence (8) · Brain Neoplasms (6) · Neoplasm Metastasis (5) · Triple Negative Breast Neoplasms (3) · Adenocarcinoma of Lung (2) · Breast Neoplasms (2) · Carcinoma, Ovarian Epithelial (2) · Endometrial Neoplasms (2) · Fallopian Tube Neoplasms (2) · Melanoma (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Cachexia (1)
Bronchial Neoplasms (101) · Carcinoma, Bronchogenic (101) · Lung Diseases (101) · Neoplasms by Site (101) · Respiratory Tract Diseases (101) · Respiratory Tract Neoplasms (101) · Thoracic Neoplasms (101) · Neoplasms (99) · Lung Neoplasms (87) · Pathological Conditions, Signs and Symptoms (14) · Pathologic Processes (13) · Disease Attributes (9) · Nervous System Diseases (7) · Brain Diseases (6) · Central Nervous System Diseases (6)
Carboplatin (9) · Pemetrexed (9) · Drug Therapy (7) · atezolizumab (6) · pembrolizumab (6) · Bevacizumab (5) · Radiosurgery (5) · Immunotherapy (4) · Platinum Compounds (4) · osimertinib (4) · Docetaxel (3) · Nivolumab (3) · anlotinib (3) · camrelizumab (3) · toripalimab (3)
Fudan University (8) · Jun Zhang, MD, PhD (4) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (3) · Memorial Sloan Kettering Cancer Center (3) · Shanghai Chest Hospital (3) · ETOP IBCSG Partners Foundation (2) · Fujian Cancer Hospital (2) · Instituto do Cancer do Estado de São Paulo (2) · Lyell Immunopharma, Inc. (2) · Maastricht University Medical Center (2) · Peking University Cancer Hospital & Institute (2) · Vestre Viken Hospital Trust (2) · Xiaorong Dong (2) · Zhejiang Cancer Hospital (2) · AIO-Studien-gGmbH (1)
China (34) · United States (19) · Italy (12) · Spain (8) · France (6) · Netherlands (6) · Taiwan (6) · Germany (5) · United Kingdom (5) · Canada (4) · South Korea (4) · Australia (3) · Austria (3) · Belgium (3) · Norway (3)
Jun Zhang, MD, PhD (4) · Zhengfei Zhu, MD (4) · Jackie Walling, MBChB, PhD (2) · Odd Terje Brustugun, MD, PhD (2) · Philippe Lambin, MD, PhD (2) · Arielle Elkrief, MD (1) · Baohui Han, M.D (1) · Chao Huang, MD (1) · Daniel Gomez, MD (1) · Daniel Tan, BSc, MBBS, PhD (1) · Dirk de Ruysscher, MD (1) · Egbert Smit, MD (1) · Fabio Arcidiacono, MD (1) · Fabio Trippa, MD (1) · Francesco Martucci, MD (1)
PMID 19403881, PMID 27441744, PMID 28973074, PMID 30982687, PMID 31067138, PMID 31908301, PMID 32388150, PMID 32484754, PMID 32539805, PMID 32822540, PMID 33107189, PMID 33688020, PMID 34430382, PMID 34526044, PMID 34787462, PMID 34903471, PMID 35094066, PMID 35243022, PMID 35492873, PMID 36161783, PMID 36288758, PMID 36358757, PMID 36801605, PMID 37105304, PMID 37435562, PMID 37451182, PMID 37754485, PMID 38104577, PMID 38684230, PMID 38830303, PMID 38862908, PMID 39398493, PMID 39751937, PMID 39756446, PMID 40898159, PMID 41546104
2016 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1)